fbpx
 

PetIQ, Bayer Announce Amicable Legal Resolution


January 30, 2019

Press release: PetIQ

PetIQ, Inc., a leading pet medication and wellness company, today announced that Bayer Healthcare LLC and PetIQ’s supplier of Advecta3 and PetLock MAX have amicably resolved Bayer’s patent infringement complaint regarding the products, and the lawsuit has been dismissed with prejudice.

Cord Christensen, PetIQ’s Chairman and Chief Executive Officer, commented, “We have a long history of acting responsibly within the industry and this remains a cornerstone of our culture at PetIQ. Litigation is a component of today’s business environment, and while we do not seek this out, it is our intention to remain vigilant, defending our Company whenever necessary. Our record of accomplishment in this regard speaks for itself and we are pleased to have this matter behind us. Our mission to make pets’ lives better with more affordable and accessible veterinarian services and products has never been stronger. We believe our category leadership, broad product portfolio, compelling service offerings, value proposition, and strong customer relationships will continue to fuel our future growth and value for our shareholders.”

PetIQ will continue to offer its customers Advecta3 and PetLock MAX flea and tick treatments and other value branded veterinarian grade medications, consistent with its mission of providing pet parents convenient access and affordable choices for pet preventative and wellness veterinary products and services.

Share This Story On:

Digital Guide

CBD Trends

This digital guide provides valuable information on the subject of CBD, including content on dosage and the importance of being fully transparent about the product’s origin

Dog & Cat Needs

With dogs and cats being members of the family, there's vital information to know in order to serve their pet parents.

Pet Nutrition

Discover how science, technology and pet owning lifestyles are changing the industry.

Enews Subscribe

53899
close
Subscribe To Pet Age
Sign up for the weekly e-newsletter, print magazine and more. Sign Up